🔗 Share this article

While the US proceeds with unprecedented changes to its vaccine recommendations, one figure appears in a surprising turn: Høeg, an American of Danish descent physician and public health researcher who initially gained attention by casting doubt on coronavirus vaccinations during the pandemic and has focused upon possible fatalities after Covid immunization in her recent time at the US Food and Drug Administration (FDA).

Proposed Changes to Childhood Vaccine Schedule

Health officials planned to announce major changes to the childhood vaccination calendar recently, bringing the US with Denmark’s national calendar, according to reports – a significant shift that would put the US out of step with many the world with no evidence for benefit. The planned update has been delayed until the coming year.

Rather than Vinay Prasad, Tracy Beth Høeg is scheduled to present at the gathering. She was just designated temporary leader of the FDA’s CDER, the fifth individual to run the office this calendar year.

A Shift at the Regulatory Body

This interim role could signify a closer partnership between the pharmaceutical and vaccine centers as Høeg and Dr. Prasad strengthen their influence at the FDA – and it suggests a increased emphasis upon dismantling long-standing vaccines at the FDA.

The new acting director has often pushed for discontinuing some pediatric shot schedules in the US so as to align more similar to the Danish model, a society with nationalized medicine and a citizenry roughly the population of Wisconsin’s.

In her initial statements, she has kept her attention on vaccines – traditionally the purview of Prasad, chief of the FDA’s vaccine center – instead of medication approval.

Doubts Over Qualifications

Dr. Høeg has no obvious background in drug development, approval processes or administrative roles, which has been customary for previous leaders of the biologics center. She has worked at the FDA as a senior adviser to the commissioner and CBER since spring.

“It seems she lacks to have the necessary background” for running the CDER, said Dr. Jonathan Howard. “She’s never run a scientific study. She is not versed in managing a sizeable institution. She has no expertise in industry regulation.”

Past heads of CBER would “understand legal statutes and the research of medication creation”, noted Dr. Janet Woodcock. “Objectively, she lacks the type of experience that former directors who headed CBER have had.”

CDER has an immense portfolio at the FDA, the former commissioner pointed out.

“Many people just zeroes in on the new drug program, but the generic program approves a multitude of generic drugs. There’s a biosimilars program, OTC medication office and so forth, and every single one must be managed,” Woodcock noted. “The area you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Additionally, a significant management component to the job, which supervises more than 5,000 staff members. “It is a massive leadership role, if you do it right,” Woodcock concluded.

Agency Reaction and Disputed Policies

In response to concerns about Høeg’s qualifications and whether this selection signifies more teamwork among regulatory chiefs on vaccines, a spokesperson responded that the “questions are based on inaccurate presumptions”.

“Her resume matches the functions of her position,” the spokesperson stated, citing the months Dr. Høeg spent guiding the FDA commissioner on “drug safety and oversight research, including computational safety modeling and immunization monitoring”.

As the temporary head, Dr. Høeg inherits the commissioner’s recently launched fast-track approval initiative, a disputed expedited therapy clearance system that reportedly troubled her predecessors. “By what process are these drugs being picked for this fast-track system? Who takes the choices?” Dr. Howard said. “There’s a lot of secrecy going on at the regulatory body right now.”

Broadly speaking, he said, “the FDA seems to be moving towards laxer regulations of most medications, with the exception of immunizations.”

Documented Past Work on Vaccines

Concerning immunizations, Høeg has a more documented, if troubling, track record, Howard have noted. She authored a study using unverified crowd-sourced reports to assess the rate of heart inflammation after COVID-19 vaccination. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have changed statistics to suggest COVID-19 vaccinations are pose a greater threat than they are.

Among her “desired changes” for the new government featured revising rules for recently developed shots and halting “optional” immunizations, she remarked after the election on a online show. At the FDA, Dr. Høeg has reportedly proposed preventing teenage boys from obtaining COVID-19 vaccinations.

“She’s an thorough true believer who begins with her conclusions and reverse-engineers to retrofit the data in a very misleading, untruthful manner,” Dr. Howard argued.

Gaining Influence and a “Push for Payback”

Høeg joined fellow dissenters, {like|